Posts

2026 Biopharma News: Filkri Approval, Langlara Interchangeability, and CDSCO ONDLS Mandate

Image
Biopharma Industry Insights 2026: New Biosimilar Approvals & Key IP Rulings The biopharmaceutical landscape continues to evolve rapidly in 2026 with critical regulatory updates, market entries, and high-stakes intellectual property decisions. In this post, we break down the most significant developments from the latest industry updates, including two major USFDA biosimilar clearances, crucial export compliance changes in India, and a landmark European Patent Office (EPO) ruling. 1. USFDA Expands Oncology Supportive Care with Filkri Approval The USFDA has officially expanded the oncology landscape by approving Filkri (filgrastim-laha) . Developed by Accord BioPharma (the U.S. speciality division of India-based Intas Pharmaceuticals ), Filkri serves as a biosimilar referencing Amgen’s blockbuster drug, Neupogen . Key Details & Market Impact: Indications: It is a short-acting granulocyte colony-stimulating factor (G-CSF) designed to stimulate neutrophil production and combat s...
Read more

Pharma IP & Biosimilars Update (May 2026): Landmark Denosumab Approvals and Europe’s Latest SPC Ruling-Safinamide

Image
Pharma IP & Biosimilars Update (May 2026): Landmark Denosumab Approvals and Europe’s Latest SPC Ruling Introduction The global pharmaceutical landscape continues to shift as high-stakes biologics face biosimilar competition and European patent courts redefine market exclusivity. This week, we analyse the surge in FDA-approved denosumab biosimilars , a strategic PBM formulary disruption , and a major legal reversal in Germany that leaves generic manufacturers exposed to patent infringement risks . 1. The Denosumab Market Explodes: 2026 FDA Biosimilar Approvals The early months of 2026 have marked an incredibly active period for bone-health therapies . The FDA has granted several key approvals that are fundamentally reshaping the denosumab competitive landscape . New 2026 Approvals & Dual-Brand Strategies Boncresa & Oziltus (denosumab-mobz): Approved on January 6, 2026, developed by Amneal and mAbxience . Amneal is deploying a dual-brand approach to target specific healt...
Location: Mumbai, Maharashtra, India
Read more